Patent · US Active

Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

US11419927B2 · kind B2 · utility

0Cited by

6References

20Claims

0Family size

Assignee

Ultimovacs ASA · NO

Inventors

Gustav Gaudernack · Sandvika, NO
Audun Tornes · Oslo, NO

Key dates

Filing date	Jun 2, 2017
Grant date	Aug 23, 2022
Priority date	—
Expiry date	Jun 2, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.